Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clarity Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$1.08 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
372.26 million
Earnings per share
-0.280
Dividend per share
N/A
Year To Date Return
-5.92%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clarity Pharmaceuticals Ltd (ASX: CU6)
Latest News
Share Fallers
Why Clarity, Qantas, Universal Store, and Westpac shares are falling today
Healthcare Shares
Why Clarity Pharmaceuticals shares just fell 5% on today's announcement
Broker Notes
3 ASX shares tipped to grow 100% or more in the next 12 months
Healthcare Shares
This ASX healthcare stock could more than double according to Canaccord Genuity
Broker Notes
This ASX healthcare stock could almost double in value according to Bell Potter
Share Gainers
Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today
Healthcare Shares
Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move
Healthcare Shares
3 ASX healthcare stocks tipped to soar over 100% higher this year
Broker Notes
Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares
Healthcare Shares
Exciting clinical news for this ASX healthcare stock earns it a buy recommendation
Share Market News
5 things to watch on the ASX 200 on Wednesday
Healthcare Shares
Why is this ASX 300 stock rocketing 17% today?
CU6 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
CU6 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Apr 2026 | $3.13 | $-0.05 | -1.57% | 1,325,739 | $3.13 | $3.21 | $3.05 |
| 10 Apr 2026 | $3.18 | $0.04 | 1.27% | 1,340,873 | $3.14 | $3.22 | $3.07 |
| 09 Apr 2026 | $3.14 | $-0.11 | -3.38% | 1,252,528 | $3.22 | $3.30 | $3.09 |
| 08 Apr 2026 | $3.25 | $0.20 | 6.56% | 2,077,942 | $3.17 | $3.31 | $3.12 |
| 07 Apr 2026 | $3.05 | $-0.10 | -3.17% | 1,557,826 | $3.17 | $3.25 | $3.03 |
| 02 Apr 2026 | $3.15 | $-0.17 | -5.12% | 1,250,156 | $3.35 | $3.41 | $3.15 |
| 01 Apr 2026 | $3.32 | $0.22 | 7.10% | 2,183,985 | $3.21 | $3.35 | $3.15 |
| 31 Mar 2026 | $3.10 | $0.07 | 2.31% | 2,313,842 | $3.08 | $3.15 | $2.96 |
| 30 Mar 2026 | $3.03 | $-0.24 | -7.34% | 2,843,796 | $3.20 | $3.23 | $2.98 |
| 27 Mar 2026 | $3.27 | $-0.06 | -1.80% | 1,039,129 | $3.26 | $3.36 | $3.18 |
| 26 Mar 2026 | $3.33 | $-0.11 | -3.20% | 1,712,096 | $3.47 | $3.53 | $3.31 |
| 25 Mar 2026 | $3.44 | $0.37 | 12.05% | 3,588,036 | $3.28 | $3.65 | $3.24 |
| 24 Mar 2026 | $3.07 | $-0.06 | -1.92% | 1,446,247 | $3.25 | $3.29 | $3.02 |
| 23 Mar 2026 | $3.13 | $-0.29 | -8.48% | 2,276,949 | $3.30 | $3.30 | $3.08 |
| 20 Mar 2026 | $3.42 | $-0.05 | -1.44% | 1,573,059 | $3.47 | $3.58 | $3.37 |
| 19 Mar 2026 | $3.47 | $-0.13 | -3.61% | 1,705,480 | $3.49 | $3.57 | $3.33 |
| 18 Mar 2026 | $3.60 | $0.20 | 5.88% | 2,572,345 | $3.45 | $3.61 | $3.31 |
| 17 Mar 2026 | $3.40 | $-0.22 | -6.08% | 5,064,800 | $4.07 | $4.26 | $3.38 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 25 Nov 2025 | Alan Taylor | Issued | 1,262,838 | $2,041,200 |
Issue of options. VWAP
|
| 25 Nov 2025 | Colin Biggin | Issued | 487,439 | $787,875 |
Issue of options. VWAP
|
| 25 Nov 2025 | Michelle Parker | Issued | 511,810 | $827,269 |
Issue of options.
|
| 01 Jul 2025 | Michelle Parker | Exercise | 500,000 | $468,750 |
Exercise of options. VWAP
|
| 01 Jul 2025 | Michelle Parker | Buy | 296,186 | $468,750 |
Exercise of options. VWAP
|
| 01 Jul 2025 | Colin Biggin | Buy | 592,373 | $937,500 |
Exercise of options. VWAP
|
| 01 Jul 2025 | Colin Biggin | Exercise | 1,000,000 | $937,500 |
Exercise of options. VWAP
|
| 01 Jul 2025 | Alan Taylor | Buy | 592,373 | $937,500 |
Exercise of options. VWAP
|
| 01 Jul 2025 | Alan Taylor | Exercise | 1,000,000 | $937,500 |
Exercise of options. VWAP
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Christopher Graham Roberts | Non-Executive Director | Mar 2016 |
Dr Roberts has 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career.
|
| Ms Rosanne Elizabeth Robinson | Lead Independent DirectorNon-Executive Director | Oct 2010 |
Ms Robinson brings over 25 years of board and executive leadership across the nuclear medicine, biotech, and health sectors, with expertise in commercial strategy, operational oversight, governance and stakeholder engagement across both public and private enterprises. She previously served as Chief Operating Officer of Cyclotek (Aust) Pty Ltd, where she led multi-site operations for radiopharmaceutical manufacturing across Australia and New Zealand. Prior to that, she was General Manager, Business Development at the Australian Nuclear Science and Technology Organisation (ANSTO).
|
| Dr Alan John Taylor | Executive ChairmanExecutive Director | Nov 2013 |
Dr Taylor has 15 years of investment banking experience focused predominantly on the life sciences sector, and has expertise in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, he was an Executive Director of Inteq Limited, a boutique Australian investment bank.
|
| Ms Michelle Parker | Executive Director | Sep 2024 |
Ms Parker has 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining the Company, she held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, team of over 35 associates responsible for end-to-end clinical trial execution.
|
| Mr Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
|
| Mr David Green | Chief Financial Officer |
-
|
|
| Robert Cochrane Vickery | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 24,366,695 | 6.55% |
| Citicorp Nominees Pty Limited | 22,096,014 | 5.94% |
| J P Morgan Nominees Australia Pty Limited | 20,704,111 | 5.57% |
| Cabbit Pty Ltd Atf Robwill Trust | 17,911,280 | 4.82% |
| Tm Ventures Pty Ltd | 16,699,842 | 4.49% |
| A.C.N. 136 437 913 Pty Ltd Atf The Taylor Family A/C | 13,266,660 | 3.57% |
| Argo Investments Limited | 12,183,274 | 3.28% |
| Pacific Custodians Pty Limited | 10,441,877 | 2.81% |
| Ubs Nominees Pty Ltd | 10,333,304 | 2.78% |
| BNP Paribas Nominees Pty Ltd, Ib Au Noms Retailclient | 9,323,748 | 2.51% |
| Yarrawah Pty Ltd Atf Peter Henderson P/L S/F A/C | 8,320,000 | 2.24% |
| BNP Paribas Noms Pty Ltd | 6,974,329 | 1.88% |
| Vantres Pty Ltd Atf Asten Super Fund A/C | 6,653,219 | 1.79% |
| Boorris Pty Ltd Atf Boorris Trust | 6,190,800 | 1.66% |
| Netwealth Investments Limited, Wrap Services A/C | 5,154,079 | 1.39% |
| Smarter Capital Pty Ltd | 5,004,543 | 1.35% |
| BNP Paribas Noms Pty Ltd, Global Markets | 4,919,066 | 1.32% |
| National Nominees Limited | 4,514,839 | 1.20% |
| Colin Biggin | 4,334,085 | 1.16% |
| Neweconomy Com Au Nominees Pty Limited | 4,032,517 | 1.07% |
